[Otosclerosis].

IF 0.9 4区 医学 Q3 MEDICINE, GENERAL & INTERNAL Orvosi hetilap Pub Date : 2024-08-11 DOI:10.1556/650.2024.33110
Bálint Liktor, Andor Hirschberg, Tamás Karosi, Balázs Liktor
{"title":"[Otosclerosis].","authors":"Bálint Liktor, Andor Hirschberg, Tamás Karosi, Balázs Liktor","doi":"10.1556/650.2024.33110","DOIUrl":null,"url":null,"abstract":"<p><p>Otosclerosis is a bone remodeling disorder with still unclear origin, which exclusively forms tiny foci in the human temporal bone. These foci most often develop in the anterior part of the oval window niche and in the stapes footplate, and mechanically fix the ossicles, causing a consequent conductive hearing loss. In relation to the treatment of otosclerosis, it is a natural demand to try to reverse the progression of the disease with various medical treatment options, but until now only bone remodeling has been slowed down. Sodium fluoride and bisphosphonate treatment have shown to be highly promising, but due to their serious side effects, they can only be considered in exceptional cases. There is still great hope for targeted (biological) therapies, but they are not yet approved in Hungary. The „gold standard” procedure for otosclerosis is the surgical solution, which does not cure the disease, just simply eliminates the conductive component of the hearing loss. The older stapedectomy is increasingly being replaced by the technically simpler stapedotomy, however, they are still considered almost equivalent procedures in the literature. In addition to standard microscopic stapes surgery, the most modern endoscopic stapedotomy is also presented. Orv Hetil. 2024; 165(32): 1237–1241.</p>","PeriodicalId":19911,"journal":{"name":"Orvosi hetilap","volume":"165 32","pages":"1237-1241"},"PeriodicalIF":0.9000,"publicationDate":"2024-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Orvosi hetilap","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1556/650.2024.33110","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Otosclerosis is a bone remodeling disorder with still unclear origin, which exclusively forms tiny foci in the human temporal bone. These foci most often develop in the anterior part of the oval window niche and in the stapes footplate, and mechanically fix the ossicles, causing a consequent conductive hearing loss. In relation to the treatment of otosclerosis, it is a natural demand to try to reverse the progression of the disease with various medical treatment options, but until now only bone remodeling has been slowed down. Sodium fluoride and bisphosphonate treatment have shown to be highly promising, but due to their serious side effects, they can only be considered in exceptional cases. There is still great hope for targeted (biological) therapies, but they are not yet approved in Hungary. The „gold standard” procedure for otosclerosis is the surgical solution, which does not cure the disease, just simply eliminates the conductive component of the hearing loss. The older stapedectomy is increasingly being replaced by the technically simpler stapedotomy, however, they are still considered almost equivalent procedures in the literature. In addition to standard microscopic stapes surgery, the most modern endoscopic stapedotomy is also presented. Orv Hetil. 2024; 165(32): 1237–1241.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
[耳硬化症]。
耳硬化是一种起源尚不清楚的骨重塑疾病,它只在人类颞骨中形成微小的病灶。这些病灶通常发生在椭圆窗位的前部和镫骨踏板,并机械地固定小骨,导致传导性听力损失。关于耳硬化的治疗,自然需要尝试用各种药物治疗方案来逆转疾病的进展,但到目前为止,只有骨重塑被减缓了。氟化钠和双膦酸钠治疗已显示出很大的希望,但由于其严重的副作用,只能在特殊情况下加以考虑。靶向(生物)治疗仍然有很大的希望,但它们尚未在匈牙利获得批准。耳硬化症的“黄金标准”是手术解决方案,它不能治愈疾病,只是简单地消除听力损失的传导成分。旧的镫骨切除术越来越多地被技术上更简单的镫骨切除术所取代,然而,它们在文献中仍然被认为是几乎相同的手术。除了标准的显微镫骨手术,最现代的内镜镫骨切开术也被提出。奥夫·海泰尔。2024;165(32): 1237 - 1241。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Orvosi hetilap
Orvosi hetilap MEDICINE, GENERAL & INTERNAL-
CiteScore
1.20
自引率
50.00%
发文量
274
期刊介绍: The journal publishes original and review papers in the fields of experimental and clinical medicine. It covers epidemiology, diagnostics, therapy and the prevention of human diseases as well as papers of medical history. Orvosi Hetilap is the oldest, still in-print, Hungarian publication and also the one-and-only weekly published scientific journal in Hungary. The strategy of the journal is based on the Curatorium of the Lajos Markusovszky Foundation and on the National and International Editorial Board. The 150 year-old journal is part of the Hungarian Cultural Heritage.
期刊最新文献
[Interdisciplinary consensus on the prevention of antiresorptive medication-related osteonecrosis of the jaw]. [Data for cultural history of malaria in Hungary]. [The role of albumin in the treatment of critically ill patients in intensive care]. [Risk of pneumonia during adalimumab therapy]. [Temporal pattern of tooth root migration following coronectomy].
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1